Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Methods of using and compositions comprising dopamine reuptake inhibitors

A technology for solvates, pharmaceuticals, in the field of racemic and optically pure metabolites

Inactive Publication Date: 2008-09-03
SEPACOR INC
View PDF37 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0009] Sibutramine has many side effects

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods of using and compositions comprising dopamine reuptake inhibitors
  • Methods of using and compositions comprising dopamine reuptake inhibitors
  • Methods of using and compositions comprising dopamine reuptake inhibitors

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 13-14

[0158] Examples 13-14 describe methods for determining the binding affinity of compounds of the invention and the binding affinities determined using these methods.

[0159] Finally, Example 15 describes oral formulations comprising compounds of the invention.

Embodiment 1

[0160] 5.1. Example 1: Synthesis of Sibutramine

[0161] Synthesis of 1-(4-Chlorophenyl)cyclobutanenitrile

[0162] To a suspension of NaH (176 g 60%, washed with hexane) in dimethyl sulfoxide (150 mL) was added chlorobenzylnitrile (303 g) over a period of 1 hour at room temperature with mechanical stirring and 1,3-dibromopropane (223 mL, 445 g). The reaction mixture was stirred for another 1 hour and isopropanol (10 ml) was slowly added to quench excess NaH. Water (150 mL) was added. The reaction mixture was extracted with tert-butyl methyl ether (MTBE) (2x200 mL), and the combined extracts were washed with water (3x200 mL), brine, and washed over MgSO 4 dry. The solvent was removed with a rotary evaporator and the final product was purified by distillation to give the title compound (22 g, 56%) as a light yellow oil, bp 110-120°C / 10 mmHg. pass the product through 1 H NMR assay.

[0163] Synthesis of 1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutylamine

[0164] A solut...

Embodiment 4

[0176] To a solution of (-)-desmethylsibutramine (0.78 g) in ethyl acetate (5 mL) was added HCl / diethyl ether (1M, 5 mL) at 0°C. The reaction mixture was stirred for 1 hour and the solid was collected by filtration. The solid was then dried to yield 068 g of a white solid. through 1 H and 13 CNMR (DMSO-d 6 ) assayed the product and determined >99% chemical purity by HPLC. [α]=-5°(c=05, H 2 O). The racemate and other enantiomers were prepared and determined in the same manner. 5.4. Example 4. (R / S)-desmethylsibutramine

[0177] Another method for the preparation of racemic desmethylsibutramine ((R / S)-DMS) is shown in Scheme 2 and described in detail below

[0178]

[0179] Process 2

[0180] Preparation of 1-(4-chlorophenyl)-1-cyclobutylcarbaldehyde

[0181] Following Scheme 2, diisobutylaluminum hydride (DIBAL-H) ​​(87 mL, 1 M in THF, 87.0 mmol) was added to 1-(4-chlorophenyl)cyclobutyronitrile ( CCBC; 10g, 521mmol) in solution. The resulting mixture was stirred...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
purityaaaaaaaaaa
Login to View More

Abstract

Methods are disclosed for the treatment and prevention of disorders and conditions including, but are not limited to, erectile dysfunction, affective disorders, weight gain, cerebral functional disorders, pain, obsessive-compulsive disorder, substance abuse, chronic disorders, anxiety, eating disorders, migraines, incontinence, depresson, attention deficit disorder, attention deficit disorder with hyperactivity, bipolar and manic conditions, dysthymic disorder, and cyclothymic disorder, senile dementia, Alzheimer's type dementia, memory loss, amnesia / amnestic syndrome, disturbance of consciousness, coma, lowering of attention, speech disorders, Parkinson's disease, Lennox syndrome, autism, epilepsy, hyperkinetic syndrome and schizophrenia. The methods comprise the administration of a dopamine reuptake inhibitor and optionally an additional pharmacologically active compound. Pharmaceutical compositions and dosage forms are also disclosed that comprise a dopamine reuptake inhibitor and optionally an additional pharmacologically active compound. Preferred dopamine reuptake inhibitors are racemic or optionally pure sibutramine metabolites, wherein the sibutramine metabolite is selected from the group consisting of (+)-desmethylsibutramine, (-)-desmethylsibutramine, (±)-desmethylsibutramine, (+)-didesmethylsibutramine, (-)-didesmethylsibutramine, and (±)-didesmethylsibutramine.

Description

[0001] This application claims the benefit of U.S Provisional Application No. 60 / 097,665, filed August 24, 1998, and U.S. Provisional Application No. 60 / 099,306, filed September 2, 1998, both of which are hereby incorporated by reference in their entirety middle. 1. Field of invention [0002] The present invention relates to methods of using dopamine reuptake inhibitors and compositions comprising dopamine reuptake inhibitors, especially racemic and optically pure metabolites of sibutramine. 2. Background of the invention [0003] Sibutramine, chemical name [N-1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl]-N,N-dimethylamine, is a neuronal monoamine Reuptake inhibitors, which were originally disclosed in US Patent Nos. 4,746,680 and 4,806,570. Sibutramine inhibits the reuptake of norepinephrine and, to a lesser extent, serotonin and dopamine. See, eg, Buckett et al., Prog Neuro-psychopharm & Biol Psychiat, 12575-584, (1988); King et al., J Clin Pharm, 26:607-611 (1989). ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/13A61K31/135A61K45/00A61KA61K31/00A61K31/11A61K31/137A61K31/166A61K35/48A61K45/06A61P1/00A61P1/08A61P3/04A61P15/10A61P25/00A61P25/06A61P25/08A61P25/16A61P25/18A61P25/22A61P25/28A61P25/30A61P43/00
CPCA61K31/135A61K45/06A61K31/137A61K31/11A61P1/00A61P1/08A61P15/10A61P25/00A61P25/06A61P25/08A61P25/16A61P25/18A61P25/22A61P25/28A61P25/30A61P3/04A61P39/00A61P43/00A61K2300/00
Inventor T·P·杰卢斯C·H·塞纳纳亚克Q·K·方
Owner SEPACOR INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com